AstraZeneca PLC logo
AstraZeneca PLC (AZN)
Compare

AstraZeneca PLC (AZN) EV/Sales Ratio: 5.14x

popular:market cap|pe ratio|revenue|price history|total return

Is AstraZeneca PLC’s EV/Sales ratio high or low?

AstraZeneca PLC's EV/Sales ratio of 5.14x is in line with its 5-year average of 5.24x, around the middle of its 5-year range (4.14x–6.68x).

As of Friday, June 12, 2026. 0.17% below its 12-month average of 5.15x.

EV/EBITDA|P/S Ratio|Revenue|All Metrics

AZN EV/Sales Ratio Chart

AZN EV/Sales Ratio
5.14x+9.59% 1Y
Zoom

AZN Average EV/Sales Ratio Chart

AZN Current vs Average EV/Sales Ratio Chart

AZN EV/Sales Ratio Metrics

EV/SALES RATIO

5.14x

EV/SALES RATIO AVG TTM

5.15x

EV/SALES RATIO AVG 3Y

5.09x

EV/SALES RATIO AVG 5Y

5.24x

EV/SALES RATIO AVG 10Y

5.12x

EV/SALES RATIO AVG 15Y

4.35x

EV/SALES RATIO AVG 20Y

3.88x

CURRENT VS TTM AVG

-0.17%

CURRENT VS 3Y AVG

+0.90%

CURRENT VS 5Y AVG

-1.97%

CURRENT VS 10Y AVG

+0.43%

CURRENT VS 15Y AVG

+18.05%

CURRENT VS 20Y AVG

+32.63%

AZN Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
AstraZeneca PLC (AZN)$282.69B5.14x5.15x5.09x5.24x
Merck & Co., Inc. (MRK)$298.29B5.22x4.33x4.75x4.77x
UnitedHealth Group Incorporated (UNH)$368.30B0.93x0.80x1.18x1.36x
Amgen Inc. (AMGN)$191.09B6.39x6.19x6.53x6.38x
Thermo Fisher Scientific Inc. (TMO)$176.77B4.81x5.13x5.38x5.61x
AbbVie Inc. (ABBV)$397.12B7.36x7.46x6.80x6.33x
Gilead Sciences, Inc. (GILD)$156.28B5.80x6.02x4.98x4.64x
Abbott Laboratories (ABT)$156.15B4.07x4.94x5.00x4.98x
Pfizer Inc. (PFE)$149.18B3.36x3.30x3.43x3.63x
Intuitive Surgical, Inc. (ISRG)$146.23B13.85x18.40x19.52x18.69x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

AstraZeneca PLC EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

AstraZeneca PLC EV/Sales Ratio FAQ

What is the EV/Sales ratio for AstraZeneca PLC (AZN)?
The EV/Sales ratio for AZN stock is 5.14x.
Is AstraZeneca PLC's EV/Sales ratio high or low?
AstraZeneca PLC's EV/Sales ratio of 5.14x is in line with its 5-year average of 5.24x, around the middle of its 5-year range (4.14x–6.68x).
What is the TTM average EV/Sales ratio for AstraZeneca PLC (AZN)?
The TTM average EV/Sales ratio for AZN stock is 5.15x.
What is the 3Y average EV/Sales ratio for AstraZeneca PLC (AZN)?
The 3Y average EV/Sales ratio for AZN stock is 5.09x.
What is the 5Y average EV/Sales ratio for AstraZeneca PLC (AZN)?
The 5Y average EV/Sales ratio for AZN stock is 5.24x.
What is the 10Y average EV/Sales ratio for AstraZeneca PLC (AZN)?
The 10Y average EV/Sales ratio for AZN stock is 5.12x.
What is the 15Y average EV/Sales ratio for AstraZeneca PLC (AZN)?
The 15Y average EV/Sales ratio for AZN stock is 4.35x.
What is the 20Y average EV/Sales ratio for AstraZeneca PLC (AZN)?
The 20Y average EV/Sales ratio for AZN stock is 3.88x.

AstraZeneca PLC EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-115.14x
2026-06-105.06x
2026-06-095.17x
2026-06-085.13x
2026-06-055.24x
2026-06-045.13x
2026-06-034.99x
2026-06-025.02x
2026-06-015.08x
2026-05-295.23x
2026-05-285.22x
2026-05-275.23x
2026-05-265.27x
2026-05-225.27x
2026-05-215.34x
2026-05-205.28x
2026-05-195.20x
2026-05-185.19x
2026-05-155.13x
2026-05-145.21x
2026-05-135.28x
2026-05-125.20x
2026-05-115.13x
2026-05-085.16x
2026-05-075.15x
2026-05-065.21x
2026-05-055.12x
2026-05-045.17x
2026-05-015.21x
2026-04-305.28x
2026-04-295.22x
2026-04-285.37x
2026-04-275.39x
2026-04-245.45x
2026-04-235.52x
2026-04-225.59x
2026-04-215.61x
2026-04-205.75x
2026-04-175.85x
2026-04-165.74x
2026-04-155.76x
2026-04-145.84x
2026-04-135.79x
2026-04-105.83x
2026-04-095.86x
2026-04-085.84x
2026-04-075.75x
2026-04-065.80x
2026-04-025.82x
2026-04-015.75x
2026-03-315.65x
2026-03-305.56x
2026-03-275.42x
2026-03-265.29x
2026-03-255.38x
2026-03-245.35x
2026-03-235.30x
2026-03-205.29x
2026-03-195.43x
2026-03-185.42x
2026-03-175.50x
2026-03-165.51x
2026-03-135.46x
2026-03-125.53x
2026-03-115.55x
2026-03-105.59x
2026-03-095.59x
2026-03-065.57x
2026-03-055.66x
2026-03-045.77x
2026-03-035.77x
2026-03-025.83x
2026-02-275.95x
2026-02-265.83x
2026-02-255.88x
2026-02-245.90x
2026-02-235.93x
2026-02-205.91x
2026-02-196.02x
2026-02-186.03x
2026-02-176.05x
2026-02-135.94x
2026-02-125.91x
2026-02-115.92x
2026-02-105.61x
2026-02-095.47x
2026-02-065.61x
2026-02-055.45x
2026-02-045.46x
2026-02-035.37x
2026-02-025.48x
2026-01-305.45x
2026-01-295.34x
2026-01-285.47x
2026-01-275.47x
2026-01-265.23x
2026-01-235.19x
2026-01-225.24x
2026-01-215.12x
2026-01-205.34x
2026-01-165.55x
2026-01-155.49x
2026-01-145.53x
2026-01-135.49x
2026-01-125.40x
2026-01-095.55x
2026-01-085.48x
2026-01-075.55x
2026-01-065.54x
2026-01-055.23x
2026-01-025.33x
2025-12-315.13x
2025-12-305.28x
2025-12-295.45x
2025-12-265.29x
2025-12-245.43x
2025-12-235.34x
2025-12-225.28x
2025-12-195.29x
2025-12-185.27x
2025-12-175.38x
2025-12-165.33x
2025-12-155.36x
2025-12-125.25x
2025-12-115.27x
2025-12-105.31x
2025-12-095.23x
2025-12-085.28x
2025-12-055.24x
2025-12-045.26x
2025-12-035.34x
2025-12-025.23x
2025-12-015.27x
2025-11-285.36x
2025-11-265.48x
2025-11-255.46x
2025-11-245.33x
2025-11-215.32x
2025-11-205.20x
2025-11-195.25x
2025-11-185.13x
2025-11-175.13x
2025-11-145.12x
2025-11-135.19x
2025-11-125.14x
2025-11-115.13x
2025-11-105.12x
2025-11-074.88x
2025-11-064.96x
2025-11-054.93x
2025-11-045.02x
2025-11-034.92x
2025-10-315.00x
2025-10-305.00x
2025-10-294.97x
2025-10-285.03x
2025-10-274.98x
2025-10-244.97x
2025-10-235.10x
2025-10-225.06x
2025-10-215.10x
2025-10-205.06x
2025-10-175.17x
2025-10-165.12x
2025-10-155.09x
2025-10-145.12x
2025-10-135.12x
2025-10-105.13x
2025-10-095.14x
2025-10-085.20x
2025-10-075.15x
2025-10-065.21x
2025-10-035.16x
2025-10-025.00x
2025-10-014.94x
2025-09-304.58x
2025-09-294.49x
2025-09-264.49x
2025-09-254.59x
2025-09-244.57x
2025-09-234.62x
2025-09-224.78x
2025-09-194.72x
2025-09-184.69x
2025-09-174.76x
2025-09-164.68x
2025-09-154.72x
2025-09-124.86x
2025-09-114.93x
2025-09-104.87x
2025-09-094.89x
2025-09-084.96x
2025-09-055.00x
2025-09-044.93x
2025-09-034.93x
2025-09-024.89x
2025-08-294.90x
2025-08-284.82x
2025-08-274.89x
2025-08-264.88x
2025-08-254.95x
2025-08-224.79x
2025-08-214.90x
2025-08-204.81x
2025-08-194.85x
2025-08-184.88x
2025-08-154.75x
2025-08-144.75x
2025-08-134.71x
2025-08-124.55x
2025-08-114.49x
2025-08-084.37x
2025-08-074.52x
2025-08-064.56x
2025-08-054.60x
2025-08-044.60x
2025-08-014.53x
2025-07-314.52x
2025-07-304.75x
2025-07-294.61x
2025-07-284.57x
2025-07-254.61x
2025-07-244.65x
2025-07-234.66x
2025-07-224.51x
2025-07-214.45x
2025-07-184.39x
2025-07-174.41x
2025-07-164.51x
2025-07-154.47x
2025-07-144.55x
2025-07-114.46x
2025-07-104.56x
2025-07-094.50x
2025-07-084.46x
2025-07-074.53x
2025-07-034.48x
2025-07-024.57x
2025-07-014.45x
2025-06-304.45x
2025-06-274.40x
2025-06-264.45x
2025-06-254.63x
2025-06-244.49x
2025-06-234.51x
2025-06-204.45x
2025-06-184.56x
2025-06-174.48x
2025-06-164.69x
2025-06-134.68x
2025-06-124.74x
2025-06-114.69x
2025-06-104.64x
2025-06-094.64x
2025-06-064.58x
2025-06-054.53x
2025-06-044.62x
2025-06-034.53x
2025-06-024.53x
2025-05-304.50x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

Related Metrics

EV/EBITDAP/S RatioRevenueAll Metrics

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Cambridge
94,300 employees
www.astrazeneca.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Pascal Claude Roland Soriot
View full financials